Costimulation of T Cell Activation by Integrin-associated Protein (CD47) Is an Adhesion-dependent, CD28-independent Signaling Pathway by Reinhold, Martina I. et al.
 
1
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/97/01/1/11 $2.00
Volume 185, Number 1, January 6, 1997 1–11
 
Costimulation of T Cell Activation by Integrin-associated
Protein (CD47) Is an Adhesion-dependent,
CD28-independent Signaling Pathway
 
By Martina I. Reinhold,
 
*
 
 Frederik P. Lindberg,
 
*
 
 Gilbert J. Kersh,
 
‡
 
Paul M. Allen,
 
‡
 
 and Eric J. Brown
 
*
 
From the 
 
*
 
Departments of Medicine, Molecular Microbiology, and Cell Biology and Physiology; and 
the 
 
‡
 
Center for Immunology and Department of Pathology, Washington University School of Medicine, 
St. Louis, Missouri 63110
 
Summary
 
The integrin-associated protein (IAP, CD47) is a 50-kD plasma membrane protein with a sin-
gle extracellular immunoglobulin variable (IgV)-like domain, a multiply membrane-spanning
segment, and alternatively spliced short cytoplasmic tails. On neutrophils, IAP has been shown
to function in a signaling complex with 
 
b
 
3
 
 integrins. However, the function of IAP on T cells,
which express little or no 
 
b
 
3
 
 integrin, is not yet defined. Here, we show that mAbs recognizing
IAP can enhance proliferation of primary human T cells in the presence of low levels of anti-
CD3, but have no effect on T cell proliferation on their own. Together with suboptimal con-
centrations of anti-CD3, engagement of IAP also enhances IL-2 production in Jurkat cells, an
apparently integrin-independent function of IAP. Nonetheless, costimulation by IAP ligation
requires cell adhesion. IAP costimulation does not require CD28. Furthermore, anti-IAP, but
not anti-CD28, synergizes with suboptimal anti-CD3 to enhance tyrosine phosphorylation of
the CD3 
 
z
 
 chain and the T cell–specific tyrosine kinase Zap70. Ligation of human IAP trans-
fected into the hemoglobin-specific 3.L2 murine T cell hybridoma costimulates activation for
IL-2 secretion both with anti-CD3 and with antigenic peptides on antigen-presenting cells
(APCs). Moreover, ligation of IAP but not CD28 can convert antagonist peptides into agonists
in 3.L2 cells. Using costimulation by IAP ligation as an assay to analyze the structure–function
relationships in IAP signaling, we find that both the extracellular and multiply membrane-span-
ning domains of IAP are necessary for synergy with the antigen receptor, but the alternatively
spliced cytoplasmic tails are not. These data demonstrate that IAP ligation initiates an adhesion-
dependent costimulatory pathway distinct from CD28. We hypothesize that anti-IAP generates
the costimulatory signal because it modulates interactions of the IgV domain with other plasma
membrane molecules; this in turn activates effector functions of the multiply membrane-span-
ning domain of IAP. This model may have general significance for how IAP functions in cell
activation.
 
I
 
ntegrin-associated protein (IAP)
 
1
 
 is a 50-kD highly hy-
drophobic cell surface glycoprotein that was originally
copurified with the 
 
a
 
v
 
b
 
3
 
 vitronectin receptor from placenta
(1) and later shown to be the antigen recognized by CD47-
specific mAb (2). Abs that recognize IAP inhibit some 
 
b
 
3
 
integrin-mediated functions, including binding of vitronec-
tin coated beads to cells, PMN activation by and chemo-
taxis to Arg–Gly–Asp (RGD)-containing ligands, and endo-
thelial [Ca
 
2
 
1
 
]
 
i
 
 increase during adhesion to fibronectin or
vitronectin (3, 4). IAP has a broader cellular distribution than
 
b
 
3
 
 integrins, suggesting that it may have functions other
than those associated with 
 
b
 
3
 
. Recently, IAP has been
shown to have a role in PMN migration across both endo-
thelial and epithelial barriers (5, 6) and to bind the large
multifunctional glycoprotein thrombospondin (7), all func-
tions without an obvious role for 
 
a
 
v
 
b
 
3
 
. Molecular cloning
of IAP cDNAs from mouse and human revealed that it is
an unusual Ig family member, with an Ig variable (IgV)-
like amino terminal extracellular domain, a domain con-
taining multiple membrane spanning segments, and a short
cytoplasmic tail (CT) with four alternatively spliced forms
(8, 9). This three-domain structure raises the possibility that
each domain plays a discrete role in IAP function, but
nothing is known about structure–function relationships of
 
1
 
Abbreviations used in this paper:
 
 CT, cytoplasmic tail; IAP, integrin-associ-
ated protein; IgV, immunoglobulin variable.
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IAP. The ubiquity of IAP expression on continuous cell
lines has hampered a systematic approach to this question.
Although IAP is highly expressed on peripheral T lympho-
cytes, which express little if any 
 
a
 
v
 
b
 
3
 
, its function in these
cells is not known. A potential role in T cell costimulation
has been suggested by recent experiments (10). Whereas
definitions of costimulation vary, in this work we have de-
fined a costimulatory molecule as one that enhances T cell
activation in response to a suboptimal antigen receptor–ini-
tiated signal. Studies using mAbs directed against potential
receptors for the costimulatory signal have identified more
than 20 different T cell surface receptors, including multi-
ple adhesion molecules, which can augment lymphocyte
mitogenesis initiated by TCR engagement (11). The co-
stimulatory receptors not only strengthen the adhesion be-
tween the antigen-responsive T cell and the APC, but also
deliver crucial costimulatory signals to facilitate cytokine
production and clonal expansion (12–14). Although CD28
is the most intensively studied costimulatory receptor, even
in this case, the specific molecular events induced by liga-
tion of CD28 required for costimulation remain uncertain.
Although they retain the ability to bind to the MHC of
the APC, antigenic peptides with mutations in the amino
acids that interact with the TCR, may be unable to activate
fully antigen-specific T cells (15, 16). These peptides, called
altered peptide ligands (APLs) can act as antagonists of T cell
activation by wild-type peptides even without competing
for MHC binding. How engagement of costimulatory mole-
cules affects T cell signals resulting from recognition of APLs is
unknown.
In the present study, we confirm that IAP can function
as a costimulator in T cell activation in both human and
mouse T cells and show that the costimulatory activity of
IAP is distinct from that of the well-defined costimulator
CD28. Furthermore, IAP ligation can convert antagonist
APL peptides into full T cell agonists, a property not shared
by CD28. Finally, using IAP costimulation as an assay to
understand structure–function relationships in IAP signal-
ing, we find that the extracellular and multiply membrane-
spanning domains of IAP are required for synergy with the
TCR, but the alternatively spliced cytoplasmic tails are not.
These studies demonstrate that T cell IAP may have im-
portant immunomodulatory effects by a mechanism dis-
tinct from that initiated by CD28 ligation.
 
Materials and Methods
 
Cell Culture.
 
Jurkat (provided by Dr. M. Thomas, Washing-
ton University School of Medicine, St. Louis, MO) and 3.L2 cells
(17) were maintained in culture in RPMI-1640 supplemented
with 10% FCS, 2 mM 
 
l
 
-glutamine, 0.1 mM NEAA, 50 mM 2-ME,
0.1% gentamicin. Transfected Jurkat and 3.L2 clones were main-
tained in the same media in the presence of 2 mg/ml or 1.5 mg/ml
Geneticin (GIBCO BRL, Gaithersburg, MD), respectively. Jurkat
and 3.L2 cells were cloned by limiting dilution.
 
DNA Constructs.
 
Standard techniques were used for nucleic
acid manipulations. PCR was performed to amplify the human
IAP transmembrane domain plus cytoplasmic tail and the cyto-
plasmic tail alone from human IAP form 2 in pBS (pIAP3) (8).
The IAP transmembrane plus cytoplasmic tail segment was ob-
tained using primers containing NheI and XbaI–SacI cloning sites
(sense oligonucleotide, 5
 
9
 
-GTTTCATGGGCTAGCCCAAAT-
GAAAATATTCTT-3
 
9
 
; anti-sense oligonucleotide, 5
 
9
 
-ATCGAG-
CTCATGGTTCTAGAACACAAGTGT-3
 
9
 
). The IAP cytoplas-
mic tail segment was obtained using primers containing SalI and
XbaI–SacI cloning sites (sense oligonucleotide, 5
 
9
 
-TTACTTG-
GACTAGGTCGACTGAAATTTGTG-3
 
9
 
; anti-sense oligonu-
cleotide as above; cloning sites are underlined). These fragments
were digested with NheI and SacI or SalI and SacI, respectively.
The cut fragments were ligated into a CD8-expressing plasmid,
CD8-8-45 in pBS (18), using the SpeI and SacI or SalI and SacI
sites. These chimeric cDNAs were cloned into the expression
vector BSR
 
a
 
EN (gift of Dr. A. Shaw, Washington University
School of Medicine, St. Louis, MO) using the XhoI and XbaI
sites. This generated two cDNAs encoding chimeric proteins.
One encodes the extracellular Ig domain of CD8 and the multi-
ply membrane-spanning and cytoplasmic domains of IAP form 2
(CD8MC2, Fig. 1). The other encodes a chimera of the extracel-
lular and transmembrane domain of CD8, and the cytoplasmic
tail of IAP form 2 (CD8C2; Fig. 1). The CD8-8-
 
*
 
 (Fig. 1) con-
struct was generated using the following primers, 5
 
9
 
-CGAT-
TAATCTAGAGAGCT-3
 
9
 
 and 5
 
9
 
-CTCTAGATTAAT-3
 
9
 
, which
generate, upon annealing, a stop codon immediately followed by
an XbaI site (underlined) plus ClaI and SacI overhangs (double
underlined). Upon annealing, this fragment was ligated into ClaI
and SacI cut CD8-8-45 in pBS, and the Xho and Xba fragment
was then subcloned into BSR
 
a
 
EN.
To generate the IAP–CD7 construct (Fig. 1), CD16–CD7–syk
(19) was used as a template for PCR amplification of the CD7
Figure 1. Schematic representation of the native and chimeric mole-
cules used in this study. Generation of the individual chimeras is described
in Materials and Methods. 
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transmembrane domain using primers that contain BamHI and
XbaI cloning sites (sense oligonucleotide, 5
 
9
 
-CCTGGGGCG-
GATCCACCAAGGGCCTCTGCC-3
 
9
 
, anti-sense oligonucle-
otide, 5
 
9
 
-ACTGTCTGCCATCTAGAGCGTCCTCGCCAG-3
 
9
 
;
cloning sites are underlined). The extracellular domain of IAP was
generated as a XhoI and BamHI fragment from pIAP 419 (un-
published data). Upon digestion of the PCR fragment with
BamHI and XbaI, both fragments were ligated into BSR
 
a
 
EN cut
with XhoI and XbaI. All PCR amplified DNA segments were
verified by DNA sequencing.
 
DNA Transfection.
 
cDNA constructs were transfected into
two independent clones each of both the Jurkat and 3.L2 cells.
Transfection of Jurkat and 3.L2 clones was conducted by elec-
troporation. Jurkat clones (5 
 
3
 
 10
 
6
 
/500 
 
m
 
l) were mixed with 15 
 
m
 
g
plasmid DNA in fresh RPMI medium at room temperature for
10 min, then electroporated at 300 V, 1,000 
 
m
 
F in a 0.4-cm cu-
vette using the Invitrogen Electroporater II. After electropora-
tion, cells were immediately placed on ice for 10 min, then resus-
pended in 10 ml RPMI medium for 24 h before transfer into
selection media (RPMI plus 2 mg/ml Geneticin). 3.L2 clones
were washed two times with cold PBS and 5 
 
3
 
 10
 
6
 
/500 
 
m
 
l were
mixed with 15 
 
m
 
g plasmid DNA in PBS and kept on ice for 10
min, then electroporated at 250 V, 1,000 
 
m
 
F in a 0.4-cm cuvette
using the Invitrogen Electroporater II. After electroporation, cells
were immediately placed on ice for 10 min, then resuspended in
10 ml RPMI medium for 24 h before transfer into selection me-
dia (RPMI plus 1.5 
 
m
 
g/ml Geneticin). In all experiments, bulk
FACS
 
Ò
 
-sorted transfectants of both transfected clones (for either
Jurkat or 3.L2) were tested. In all cases, data obtained from both
clones were similar. Thus, data from single transfected clones are
presented. In some assays, transfected cell populations were sorted
a second time to obtain populations with high level of expression
of transfected molecules.
 
Isolation of T Cells.
 
PBMCs from healthy donors were sepa-
rated by Ficoll–HyPaque density gradient centrifugation. Adher-
ent cells were eliminated by culture for several hours on tissue
culture–treated plastic. B cells were deleted by immunomagnetic
negative selection using Dynabeads M-450 coupled to the pan B
cell antigen CD19 (Dynal, Inc., Great Neck, NY). The purity of
the isolated T cells was 
 
.
 
90% as assessed by immunofluorescent
analysis using anti-CD3 and anti-CD19 and fluorescent flow cy-
tometry (EPICS XL; Coulter Corp., Hialeah, FL).
 
mAbs.
 
The following mAbs were used in these studies: 2E11,
2D3, B6H12 (IgG1, murine anti–huIAP; 1, 20); W6/32 (IgG1,
murine anti–HLA; 21); OKT3 (IgG2a, murine anti–huCD3); and
53.67 (IgG2a, rat anti–muCD8
 
a
 
) were purchased from the
American Type Culture Collection (Rockville, MD); 9.3 IA1
(IgG2a, murine anti–huCD28 was provided by Dr. J. Ledbetter,
Bristol-Myers, Squibb, Seattle, WA); 37.51 (IgG, hamster anti–
muCD28, purchased from PharMingen, San Diego, CA); 145-
2C11(IgG, hamster anti–muCD3; 22); IB4 (IgG1, murine anti–
huCD18; 23); YTS 213.1 (IgG2a, rat anti–muCD18; purchased
from BioSource, CA); YTS105.18 and KT15 (IgG2a, rat anti–
muCD8; purchased from Serotec, Ltd., Oxford, England); 3D9
(IgG1, murine anti–CD35; 24); 7G2 (IgG1, murine anti–hu
 
b
 
3
 
;
20); P5D2 (IgG1, murine anti–hu
 
b
 
1
 
; Developmental Studies Hy-
bridoma Bank, Iowa City, IA; 25); rabbit anti–
 
z
 
 chain peptide
antiserum (P. Allen, unpublished data); rabbit anti-Zap70 peptide
antiserum (provided by Dr. A. Chan, Washington University, St.
Louis, MO); 2E11, 2D3, IB4 IgG were purified from ascites us-
ing octanoic acid as described (26). SDS-PAGE of all purified
IgG preparations showed them to be 
 
.
 
90% IgG.
 
Flow Cytometry.
 
Cells were stained with saturating concen-
trations of antibody, then incubated with fluorescein-conjugated
goat anti–mouse or goat anti–rat Ab before analysis in a FACScan
 
Ò
 
(EPICS XL; Coulter) as previously described (1). 3.L2 cells were
precoated with saturating concentration of human IgG to block
FcR expressed on these cells.
 
Preparation of Antibody-coated Microtiter Plates.
 
Flat-bottomed
microtiter plates (3595 Costar, Cambridge, MA) were precoated
overnight at 4
 
8
 
C with 5 
 
m
 
g/ml of either goat anti–mouse or a
mixture of goat anti–mouse plus goat anti–rat or anti–hamster
IgG antibodies (Organon Teknika, Durham, NC) (70 
 
m
 
l/well in
20 mM sodium bicarbonate buffer, pH 9.0). Additional protein
binding sites were blocked by overnight treatment with 2% BSA
in RPMI-1640 at 4
 
8
 
C. Plates were washed three times with PBS
and individual stimulating Abs were added in a 100 
 
m
 
l volume
(final volume per well was 200 
 
m
 
l) and incubated overnight at
4
 
8
 
C. OKT3 supernatant was used in 10-fold dilutions for dose–
response curves. Anti-IAP or control anti-KLH were used at 10-
fold dilutions of supernatant. All other Abs were used at 1 
 
m
 
g/ml
or as indicated.
 
Proliferation Assays.
 
Proliferation assays were performed using
standard techniques. In brief, 40,000 purified T cells/microtiter
well in 100 
 
m
 
l were cultured in the mAb precoated plates for 3 d in
RPMI media and pulsed with a [
 
3
 
H]thymidine solution (1 
 
m
 
Ci/well,
6.7 Ci/mmol specific activity, ICN) during the last 18 h before
harvesting.
 
Production of IL-2.
 
 1 
 
3
 
 10
 
5
 
 Jurkat or 3.L2 cells/well were
cultured for 24 h in the mAb precoated 96-well microtiter
plates, after which the supernantants from these cultures were
collected and added to the IL-2-dependent CTLL-2 line for 48 h
and pulsed over the last 18 h with [
 
3
 
H]thymidine (0.4 
 
m
 
Ci/well,
6.7 Ci/mmol specific activity, ICN) (27). For activation of the
3.L2 hybridoma in the presence of APC, 1 
 
3
 
 10
 
5
 
 3.L2 cells were
cultured in 200 
 
m
 
l of RPMI media for 24 h with APC (2 
 
3
 
 10
 
4
 
,
CH27), mAbs and the stated peptide concentrations. Superna-
tants (100 
 
m
 
l) were removed and added to the IL-2 dependent
CTLL-2 line and assayed as above. In some assays, dilutions of
IL-2 containing supernatants were used and compared with an
IL-2 standard curve to quantitate IL-2 production.
 
Immunoprecipitations and Immunoblots.
 
Jurkat cells (10
 
6
 
cells/pt
for 
 
z
 
 chain and 5 
 
3
 
 10
 
6
 
 cells/pt for Zap70) were incubated on
Ab-coated surfaces at 37
 
8
 
C for 5–15 min, as indicated in the text.
Cells were lysed in 1% NP-40, 0.5% DOC, 50 mM Hepes (pH
7.5), 150 mM NaCl, 20 mM NaF, 1 mM EDTA, 10 
 
m
 
g/ml leu-
peptin and aprotinin, 10 mM betaglycerophosphate, 50 nM caly-
culin, and 250 
 
m
 
M sodium vanadate. Insoluble material was re-
moved by centrifugation at 13,000 
 
g
 
 for 5 min. Prepared cell
lysates were immunoprecipitated for 3 h by incubation at 4
 
8
 
C
with Ab and protein A–Sepharose (CL-4B; Pharmacia), followed
by washing of the immunoprecipitates with lysis buffer before
further analysis. Immunoprecipitated proteins were separated by
SDS-PAGE and transferred to nitrocellulose membranes. West-
ern blots were performed as described (28) and developed with
4G10 antiphosphotyrosine mAb (UBI, Lake Placid, NY) or with
polyclonal antiprotein antibodies to assure equal loading of sam-
ple into each lane. 
 
z
 
 chain and Zap70 tyrosine phosphorylation
were quantitated by densitometric scanning of the exposed x-ray
films. In all cases, experimental results were compared with con-
trol lanes on the same gel of 
 
z
 
 or Zap70 from cells adherent to the
noncostimulatory combination of low concentration anti-CD3
together with anti-HLA. In each experiment, this control level of
tyrosine phosphorylation was assigned a density of 1 and experi-
mental values compared with this density. Means of independent
experiments were obtained using these values, and comparisons 
4
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between costimulatory and noncostimulatory conditions evalu-
ated using a two-tailed Student’s 
 
t
 
 test.
 
Results
Anti-IAP and Anti-CD3 Costimulate Human PBL Prolifer-
ation and IL-2 Production by Jurkat and HUT78. To inves-
tigate the function of IAP on lymphocytes, we evaluated its
role in T cell activation. When human T lymphocytes were
purified from peripheral blood, no concentration of anti-
IAP alone stimulated proliferation (data not shown). In
contrast, when combined with a suboptimal concentration
of anti-CD3, three different anti-IAP mAbs enhanced
proliferation of purified peripheral blood T cells. Using the
same low concentration of anti-CD3, the nonbinding iso-
type-matched negative control 3D9 (anti-CR1/CD35)
(Fig. 2 A) and mAb W6/32 (anti-HLA), which binds to a
different cell surface antigen (data not shown), did not sig-
nificantly enhance proliferation. In contrast with assays in
which IAP has been shown to function with b3 integrins,
the anti-IAP mAb B6H12 was much less potent than anti-
IAP 2D3, which recognizes a distinct epitope on the Ig do-
main (1) (data not shown). This suggested the possibility
that the role for IAP is different in synergy with anti-CD3
than in cooperation with b3 integrins. 2E11, an anti-IAP
mAb recognizing a third distinct epitope, also was costimu-
latory. Anti-IAP mAbs 2E11 and 2D3 also synergized with
suboptimal concentrations of anti-CD3 to increase IL-2
production in Jurkat cells, while anti-HLA did not (Fig. 2 B;
data not shown). This synergy is unlikely to be dependent
on IAP cooperation with an integrin, since mAbs against
b1, b2, and b3 integrins did not increase T cell prolifera-
tion or Jurkat IL-2 production in combination with anti-
CD3 (data not shown). The avb3 ligand vitronectin also
was unable to costimulate T cell proliferation or Jurkat IL-2
production with suboptimal anti-CD3 (data not shown).
These results imply that IAP enhancement of IL-2 produc-
tion and T cell proliferation is independent of IAP association
with integrins. For costimulation, anti-IAP and anti-CD3
had to be on the same surface. If either or both antibodies
were used in solution, there was no costimulation even
when the antibodies were cross-linked with a secondary
antibody (data not shown). This suggests that the costimu-
latory signal arises from adhesion to a surface presenting
ligands for both IAP and the TCR complex. When IL-2
production was quantitated, IAP-mediated enhancement of
IL-2 production with low concentration of anti-CD3 was
similar to that seen with the well characterized costimulator
CD28 (Fig. 2 B). To determine whether costimulation by
IAP required CD28, we tested whether IAP was able to
augment IL-2 production in the CD28 deficient human
cutaneous T cell lymphoma, HUT 78. Although without
effect on their own, anti-IAP Abs enhanced IL-2 produc-
tion with suboptimal anti-CD3 in HUT 78, equivalent to
their effect in Jurkat cells (data not shown). Thus, anti-
IAP-mediated costimulation does not require expression of
CD28.
Costimulation with Anti-IAP Abs but Not Anti-CD28 Re-
sults in Enhanced TCR z Chain and Zap70 Phosphoryla-
tion. One of the earliest events in T cell activation is the
tyrosine phosphorylation of the TCR z chain and the syk
family tyrosine kinase Zap70. To determine whether co-
Figure 2. IAP synergy with CD3. (A) Human peripheral blood T cells
were incubated on plates coated with a low concentration of anti-CD3
together with increasing concentrations of anti-IAP mAb 2E11 or 2D3,
or anti-CR1 (3D9). Cells were pulsed with [3H]thymidine for the last 16 h
of a 90 h incubation. Shown are averages of triplicate wells from 1 ex-
periment of .3 with similar results. Cells plated on 2E11, 2D3, and 3D9
alone had ,1,000 CPM. Maximum stimulation by high concentration of
anti-CD3 was 40,000 cpm. (B) Jurkat cells were incubated on plates
coated with increasing concentrations of anti-CD3 and the same concen-
tration of anti-IAP (2D3), anti CD28 (9.3), or anti-HLA (W6/32) mAbs.
Supernatants were harvested after 24 h and IL-2 concentration measured
by assay on CTLL-2 cells. The values shown represent triplicates of
[3H]thymidine incorporation by the CTLL-2 cells in 1 experiment of .3
with similar results. Quantitation of IL-2 concentration showed that stim-
ulation of Jurkat cells by low levels of anti CD3 (1) in the presence of
anti-IAP or anti-CD28 mAbs led to 1 U/ml, compared with 0.1 U/ml
for the negative control mAb. Neither anti-IAP or anti-HLA caused de-
tectable IL-2 secretion in the absence of anti-CD3. Additional mAbs that
do not costimulate with anti-CD3 include anti-CD61 (integrin b3), anti-
CD18 (integrin b2), and anti-CD29 (integrin b1).5 Reinhold et al.
stimulation by IAP affects the phosphorylation status of z
and Zap70, we analyzed z chain and Zap70 immunopre-
cipitates after activation of Jurkat clones under costimula-
tory (low anti-CD3 plus anti-IAP or anti-CD28) and con-
trol conditions (low anti-CD3 plus anti-HLA). We found
that z chain tyrosine phosphorylation in the presence of
anti-IAP mAbs was enhanced over control and was almost
equivalent to optimal anti-CD3 (Fig. 3, A and B). In con-
trast, the costimulatory combination of anti-CD28 with
anti-CD3 did not enhance z chain tyrosine phosphoryla-
tion. Similarly, Zap70 phosphorylation was equivalent for
optimal anti-CD3 and the costimulatory combination of
CD3 and IAP mAb. In contrast, anti-CD28 did not co-
stimulate Zap70 phosphorylation above control levels (Fig.
3, C and D). These data demonstrate that IAP-mediated
costimulation occurs by a signaling pathway distinct from
that initiated by CD28.
Transfected Human IAP Costimulates a Murine T Cell Hy-
bridoma. To begin to understand IAP function in T cell
Figure 3. Costimulation with anti-IAP and not anti-CD28 results in
enhanced z chain and Zap70 tyrosine phosphorylation. (A and C) Jurkat
cells (106cells, A; 5 3 106 cells, C) were stimulated for the indicated time-
points with either an optimal high concentration of anti-CD3 (100) or a
low concentration of anti-CD3 (1) coimmobilized with anti-IAP, anti-
HLA, or anti-CD28. Cell lysates were immunoprecipitated with anti-z
chain (A) or anti-Zap70 (C) polyclonal Abs and analyzed by SDS-PAGE
followed by Western blotting with antiphosphotyrosine. (B and D) z
chain and Zap70 tyrosine phosphorylation expressed as fold increase over
control noncostimulatory conditions (low anti-CD3 plus anti-HLA). Bars
represent the mean and SEM of three independent experiments at either
5 min (B) or 15 min (D). Phosphorylation of both z chain and Zap70 was
increased by cell adhesion to the costimulatory combination of anti-CD3
and anti-IAP compared to control and compared with adhesion to anti-
CD3 and anti-CD28 (P ,0.05 in all cases). In contrast, adhesion to the
costimulatory combination of anti-CD3 and anti-CD28 did not stimulate
z chain or Zap70 phosphorylation compared with control.
Figure 4. hIAP and chimera expression in Jurkat and 3.L2 subclones.
Expression of native hIAP and chimeric constructs was determined by
staining with mouse anti–hIAP IgG1 (2E11) or rat anti–murine CD8a
(dotted lines), or isotype-matched control (7G2 or 313, respectively, solid
lines) mAbs as described in Materials and Methods. Shown are profiles of
one of the transfected Jurkat or 3.L2 clones, with similar levels of expres-
sion in the second clone transfected.6 IAP in T Cell Activation
costimulation, we transfected form 2 of human IAP (hIAP),
which is the predominant IAP form found in leukocytes,
into two independent clones of the hemoglobin-specific
murine T cell hybridoma 3.L2 (Fig. 4) (17). Initial experi-
ments using the 3.L2 clones showed that mAbs recognizing
CD28 costimulated IL-2 production with suboptimal anti-
CD3, indicating that this murine hybridoma was respon-
sive to costimulatory signals. Coligation of hIAP with anti-
hIAP mAbs, which do not cross-react with mouse IAP,
and suboptimal anti-CD3 also resulted in enhanced IL-2
production over control mAb (Fig. 5 A).
Anti-IAP and Antigen Costimulate 3.L2 Transfectants. The
TCR of the 3.L2 mouse hybridoma is known to recognize
a peptide sequence, (Hb 64–76), from the murine b-minor
chain of hemoglobin protein in the context of MHC class
II (I-Ek) (17). This peptide, when presented by the B cell
lymphoma CH27, stimulates a dose dependent induction
of 3.L2 activation. When the 3.L2 clones transfected with
human IAP form 2 were incubated with antigenic peptide,
addition of anti-IAP mAbs 2D3 (and 2E11; data not
shown) stimulated a marked increase in IL-2 production at
low peptide concentrations (Fig. 5 B). No increase in IL-2
production was observed upon addition of an anti-CD28
mAb. At an optimal peptide concentration, anti-IAP had
no costimulator effect. Thus, in both antigen- and anti-
CD3-stimulated T cell activation, ligation of IAP alters the
sensitivity of cell activation to TCR ligation, but does not
affect maximal response.
F(ab9)2 of these anti-hIAP mAb failed to costimulate (data
not shown), suggesting that binding to the APC via its FcR
Figure 5. IL-2 production by 3.L2 clones transfected with hIAP form
2. (A) Anti-CD3 was coimmobilized at the indicated concentration with
anti-CD28, anti-hIAP (2E11, 2D3), or control mAb (YTS 213.1). 3.L2
clones, transfected with hIAP (form 2) were plated at 1 3 105 cells/well.
Supernatants were harvested after 24 h and IL-2 concentration measured as
described in Fig. 2 B. (B) 3.L2 clones transfected with hIAP (form 2) at 1 3
105 cells/well were activated with the indicated amounts of Hb(64–76)
peptide presented by CH27 cells (2 3 104 cells/well) in the presence of
anti-IAP mAbs 2D3 or B6H12, anti CD28 (37.51) or a control mAb
(IB4). T cell hybridoma activation was measured by IL-2 production after
24 h of culture as described in Fig. 2 B. Neither anti-IAP or control Ab
alone caused detectable IL-2 production. The values shown represent av-
erages of triplicates of 1 experiment of .3 with similar results.
Figure 6. IAP can convert antagonist peptides I72 and A72 to agonists.
3.L2 clones transfected with hIAP form 2 (closed symbol) or IAP/CD7
(open symbol) were activated with the indicated concentration of the
Hb(64–76)–I72 (A) or Hb(64–76)–A72 (B) peptide presented by CH27
cells in the presence of anti-IAP mAbs 2E11, 2D3 or B6H12, anti CD28
(37.51), or a control mAb (IB4). I72 and A72 have been shown previ-
ously to have significant antagonist but no activating effects on 3.L2 (30).
T cell activation was measured as described in Fig. 2 B. The values shown
represent averages of triplicates of 1 experiment of .3 with similar results.7 Reinhold et al.
was required for the anti-IAP mAb to act as a costimulator.
This is consistent with the observation in human cells that
the signal for costimulation arises from adhesion to a sur-
face expressing both antigen receptor (CD3) and IAP
ligands. The increase in IL-2 production was not simply a
result of enhanced interaction between the APC and the T
cell, since a third anti-human IAP mAb, B6H12, which has
equal affinity for human IAP as 2E11 or 2D3, did not en-
hance IL-2 production above background levels (Fig. 5 B).
Stimulation by anti-IAP mAb 2D3 and failure of B6H12 to
stimulate is in direct contrast with the effects of these mAbs
on integrin b3-dependent functions (8, 29), emphasizing
the independence of T cell costimulation from IAP–inte-
grin association.
IAP Ligation Alters 3.L2 Response to APL Peptides. To test
whether the nature of the peptide ligand affected the ability
of IAP to costimulate T cell activation, the effects of APL
peptides on 3.L2 activation were tested. The two antago-
nist peptides chosen were previously shown to have no ag-
onist effects on 3.L2 (30), because they did not induce any
IL-2 production from 3.L2 cells on their own even at con-
centrations above 100 mM. When tested in combination
with anti-IAP, both peptides induced the T cell hybridoma
to make IL-2 (Fig. 6). In contrast, addition of anti-CD28
mAb did not result in IL-2 production by the 3.L2 clones.
Thus, coligation of IAP but not CD28 with the antigen re-
ceptor gives a fully activating signal, even with peptides inca-
pable of producing any activating signal on their own. 
IAP Cytoplasmic Tail Is Not Required for Costimulation.
To begin to understand the domains of IAP required for
costimulation, we tested whether the cytoplasmic tail of
IAP is required for costimulatory activity. IAP form 1,
which has a cytoplasmic tail of only four amino acids, is a
naturally occurring form of IAP expressed in keratinocytes
and several transformed cell lines (9). 3.L2 clones trans-
fected with hIAP form 1 (see Fig. 4) were tested for their
ability to synergize with anti-CD3. All anti-human IAP
mAbs tested (2E11, 2D3, or B6H12) were able to costimu-
late IL-2 production in these cells (Fig. 7 A). 3.L2 transfec-
tants expressing the tailless form of IAP also were tested
with antigenic peptide. In these transfectants, the addition
of anti-hIAP mAbs 2E11 or 2D3 resulted in a marked in-
crease in IL-2 production (Fig. 7 B). Thus, in two assays, the
IAP cytoplasmic tail was not required for costimulation.
The IAP Multiply Membrane-spanning Domain Is Required
for T Cell Costimulation. To determine whether the IAP
Ig domain alone is able to enhance IL-2 production, we re-
placed the multiply membrane-spanning domain and cyto-
plasmic tail of IAP with the CD7 transmembrane domain
(see Fig. 1). All anti-IAP mAbs recognized this chimeric
protein when expressed in the 3.L2 clones (see Fig. 4).
Moreover, this construct restored vitronectin bead binding
when transfected into an IAP-deficient cell expressing avb3
and avb5 integrins (31). Thus, both mAb and functional
data suggest that the Ig domain conformation was unal-
tered. Nonetheless, ligation of IAP/CD7 did not costimu-
late in either 3.L2 clone (Fig. 8 A). These results show that
the extracellular domain of IAP is not sufficient to syner-
gize with anti-CD3.
The multiply membrane-spanning domain was required
for IAP costimulation in antigen presentation as well, since
IAP/CD7 transfectants failed to enhance IL-2 production
in response to either of the stimulating anti-human IAP
mAbs in combination with low concentrations of stimulat-
ing peptide (Fig. 8 B). To eliminate the possibility that the
lower level of expression of IAP/CD7 contributed to the
inability of this chimera to costimulate, we generated 3.L2
clones expressing equivalent levels of IAP/CD7 and wild-
type human IAP as determined by FACSÒ staining. Still,
IAP/CD7 did not costimulate IL-2 production at all (data
not shown). Thus, in a direct antigen stimulation assay, the
Ig and multiply membrane spanning domain are sufficient
to costimulate T cell activation (see Fig. 7 B), while the
IAP Ig domain fails to activate (Fig. 8 B). Failure of costim-
Figure 7. Anti-IAP costimulates IL-2 production in 3.L2 clones trans-
fected with hIAP form 1. (A) 3.L2 clones, transfected with hIAP form 1,
were cultured on surfaces coated with anti-CD3 at the indicated concen-
tration plus anti-CD28 (37.51), anti-hIAP (2E11, 2D3), or control mAb
(YTS 213.1) and IL-2 production was measured. (B) 3.L2 clones, trans-
fected with hIAP form 1, were activated with the indicated concentration
of Hb(64–76) peptide in the presence of anti-IAP mAbs 2E11, 2D3, or
B6H12 or a control mAb (IB4). T cell activation was analyzed as de-
scribed in Fig. 2 B. The values shown represent averages of triplicates of 1
experiment of .3 with similar results.8 IAP in T Cell Activation
ulation by IAP/CD7 also is further evidence that mAb-
mediated aggregation of APCs and T cells is not sufficient
to account for the role of IAP in T cell activation.
The Multiply Membrane-spanning Domain of IAP Is Not
Sufficient for T Cell Costimulation. To determine whether
the multiply membrane-spanning domain of IAP was suffi-
cient for IAP function, we replaced the IAP extracellular
domain with that of mouse CD8a (CD8MC2). We used
IAP form 2 for the chimeric construct because this is the
endogenous form of IAP expressed in T cells and in the Jurkat
cell line. Control chimeras consisting of the mouse CD8a
extracellular and transmembrane domain with (CD8C2;
see Fig. 1) and without (CD8*; see Fig. 1) the IAP cyto-
plasmic tail also were transfected (see Fig. 4; data not
shown). Jurkat clones expressing the CD8 constructs did
not show costimulatory activity when activated by a low
concentration of anti-CD3 and any of three different anti-
CD8 mAbs tested (Fig. 9 A; data not shown). As for all
cDNAs, these chimeras were transfected into two indepen-
dent Jurkat clones each, with identical results. Expression
of the chimeric molecules did not prevent costimulation of
Jurkat cells, since activation of the endogenous IAP with
2E11 mAb still resulted in elevated IL-2 levels (Fig. 9 A).
To test the CD8MC2 chimera in the antigen-induced acti-
vation, it was transfected into two 3.L2 clones (see Fig. 4).
Anti-CD8 mAbs failed to enhance IL-2 production over
background in this assay as well (Fig. 9 B). To rule out the
possibility that low expression of the chimera led to failure
to costimulate, a transfectant population was selected stably
expressing fivefold more CD8MC2. Although these clones
Figure 8. IAP/CD7 cannot costimulate IL-2 production. (A) 3.L2
clones, transfected with IAP/CD7, were plated on plates coated with
CD3 at the indicated concentration in the presence of either anti-CD28
(37.51), anti-hIAP (2E11, 2D3), or control mAb (YTS 213.1). (B) IAP/
CD7-transfected 3.L2 clones (open symbol) or hIAP form 2 (closed symbol)
were activated with the indicated concentration of Hb(64–76) peptide in
the presence of anti-IAP mAbs 2E11, 2D3, or B6H12, or a control mAb
(IB4) and T cell activation was analyzed. The values shown represent av-
erages of triplicates of 1 experiment of .3 with similar results.
Figure 9. The multiply membrane-spanning domain of IAP is not
sufficient for T cell costimulation. (A) Jurkat clones, transfected with
CD8MC2, were cultured on plates coated with anti-CD3 plus anti-
CD28 (9.3), anti-IAP (2E11), two different anti-CD8 (YTS, KT15), or
control mAb (IB4). Supernatants were harvested after 24 h and IL-2 con-
centration measured using CTLL-2 as described in Fig. 2 B. A third anti-
CD8 mAb (53.67) also failed to costimulate these transfected Jurkat cells.
(B) 3.L2 clones transfected with CD8MC2 (open symbols) or hIAP form 2
(closed symbol) were activated by the indicated amounts of Hb(64-76)
peptide presented by CH27 cells in the presence of anti-IAP (2D3), anti-
CD8 (53.67; KT15; YTS), or control (anti-KLH) mAb and IL-2 produc-
tion was measured. The values represent averages of triplicates of 1 exper-
iment of .3 with similar results.9 Reinhold et al.
expressed the chimera at a level equivalent to expression of
the wild-type human IAP, anti-CD8 still failed to costimu-
late IL-2 production (data not shown).
Discussion
IAP (CD47) is an Ig family member highly expressed on
lymphocytes, but without known function on these cells.
In the present work, we describe a role for IAP in costimu-
lation of T cell activation in combination either with low
dose anti-CD3 or with antigen. Costimulation is a funda-
mental requirement for optimal T cell activation. The best
understood costimulatory signal comes from the interaction
of B7 with its receptor CD28. This interaction leads to in-
tracellular signals that result in enhanced IL-2 production
and the prevention of anergy (32). In addition to CD28,
other molecules on the surface of T cells have been im-
plicated in costimulation. These include a variety of adhe-
sion receptors, including integrins recognizing fibronectin,
ICAM-1, and laminin (33–35). However, little is known
about the mechanism by which adhesion receptors cooper-
ate with the antigen receptor, or about structural require-
ments for adhesion receptor function in this important bio-
logical response. In particular, previous experiments have
failed to demonstrate rigorously that costimulation by ad-
hesion molecules requires signaling through the adhesion
receptor. It is possible that the enhancement of the antigen
receptor signal simply represented increased efficiency of
interaction of the antigen receptor with ligand or antibody
due to enhanced contact with the activating surface.
The close relationship between IAP and the integrin
avb3 led us to examine whether IAP could costimulate
T cell activation like other adhesion receptors. Indeed, this
was the case, as we have shown both in an assay using anti-
CD3 and another involving presentation of specific antigen
in the context of MHC. Despite the requirement for cell
adhesion in IAP costimulation, two lines of evidence sug-
gest that the effect of IAP ligation in these assay is inde-
pendent of integrins. First, in Jurkat cells, ligation of IAP
costimulated IL-2 production, but this effect was not mim-
icked by ligation of any integrin on the cell. This is also
true in 3.L2 cells, in which ligation of transfected human
IAP effectively costimulated proliferation, while ligation of
endogenous b1 or b2 integrins did not (data not shown).
Second, the effects of specific anti-IAP mAb were very dif-
ferent in T cell costimulation than in b3 integrin-depen-
dent functions. Multiple studies have shown that anti-IAP
mAb B6H12 is functionally active, whereas the mAb 2D3,
which has the same affinity for IAP, is not (8, 29). Since
B6H12 and 2D3 both recognize the IAP Ig domain but
have different noncompetitive epitopes, these data suggest
that B6H12 recognizes a site on the extracellular domain
necessary for functional interaction with b3 integrins, whereas
2D3 does not. In contrast, both in the antigen-dependent
assay for IAP costimulation and in the anti-CD3-depen-
dent costimulation of peripheral blood T cells, B6H12 was
less effective than 2D3. These data suggest that the IAP Ig
domain has a different role in T cell costimulation than in
functional association with b3 integrins.
The adhesion-dependent costimulatory activity of IAP is
distinct from CD28. First, expression of CD28 is not re-
quired for IAP to enhance IL-2 production, as shown by
the CD28-deficient T cell lymphoma HUT 78. Second,
although IAP or CD28 can synergize equally well with low
concentration of anti-CD3 to enhance IL-2 production in
Jurkat cells, only IAP synergizes with CD3 to promote z
chain and Zap70 phosphorylation. Thus, the mechanism of
IAP costimulation is quite different from CD28. This dis-
tinction is supported by the finding that addition of anti-
IAP, but not anti-CD28 mAbs, converted the antagonistic
APL peptides into agonists, resulting in efficient IL-2 pro-
duction by the 3.L2 T cell hybridoma.
Studies of costimulation by chimeric molecules contain-
ing IAP domains demonstrate that molecules lacking either
the Ig domain or the multiply membrane-spanning domain
fail to costimulate. This suggests that each domain is in-
volved in a function required for costimulation. On the
other hand, there appears to be no essential role for the IAP
cytoplasmic tail in costimulation, since IAP form 1 (which
has only four amino acids in its cytoplasmic tail) is as effec-
tive as form 2, the major leukocyte form of IAP, which has
a 15–amino acid cytoplasmic tail. Of course, this does not
rule out interaction of IAP with specific cytosolic proteins
via the short hydrophilic sequences in the multiply mem-
brane-spanning domain that link the transmembrane se-
quences. Importantly, the described studies do rule out the
possibility that anti-IAP nonspecifically enhances interac-
tion of CD3 with anti-CD3 or of TCR with peptide and
MHC. Antibodies that are effective for costimulation on
wild-type IAP fail to costimulate the IAP/CD7 chimera,
despite expression of the identical epitope for the mAb in
both molecules. Moreover, a mAb (B6H12) with equal af-
finity to these costimulatory antibodies fails to costimulate.
Thus, ligation of IAP must generate a signal that cannot oc-
cur with suboptimal anti-CD3 or peptide, no matter how
efficiently they are presented to the T cell. This conclusion
is reinforced by the studies with altered peptide ligand that
also cannot activate T cells on their own at any concentra-
tion, but that are effective stimulators in association with
IAP ligation. Because ligation of IAP cannot lead to IL-2
synthesis on its own and can only effectively costimulate
when presented on the same surface as anti-CD3 or acti-
vating peptide, the costimulatory effect of IAP apparently
requires the physical proximity of the TCR complex. The
observation that IAP enhances z chain and Zap70 phos-
phorylation under the costimulatory conditions suggests
that IAP ligation may modify a TCR-generated signal; al-
ternatively, the cytoplasmic domains of molecules in the
TCR complex may serve as interaction sites for cytoplas-
mic molecules affected by the signal(s) generated from IAP
ligation.
The requirement for the multiply membrane-spanning
domain suggests that this region of IAP is involved in some
signaling function of the molecule. A role for IAP as a10 IAP in T Cell Activation
membrane Ca21 channel has been proposed (4). If this is
the mechanism by which IAP affects costimulation, the in-
crease in [Ca21]i generated by IAP ligation would likely be
only in a small part of the cell, given the requirement that
IAP and CD3 must be in close proximity for effective co-
stimulation. Alternatively, the multiply membrane span-
ning domain could provide a docking site for cytoplasmic
molecules that are involved in antigen receptor–mediated
signal transduction. A similar role has recently been pro-
posed for CD20, a B cell surface antigen that cooperates
with the B cell antigen receptor in cell activation. CD20
has a domain that is thought to have four membrane-span-
ning regions. This highly hydrophobic domain has been
shown to associate with src family tyrosine kinases (36),
which is thought to be the mechanism by which CD20
contributes to B cell activation.
The inability of the CD8 Ig domain to substitute for the
IAP Ig domain is very surprising. Quite often in immune
signaling, the effector domains are intracytoplasmic, or mem-
brane and cytoplasmic, and ligand or antibody generates a
signal by aggregation of these effector domains. In this
model, the exact nature of the extracellular domain is irrel-
evant, as long as it can be aggregated by antibodies (19, 37,
38). This cannot be the case for IAP, because the CD8 ex-
tracellular domain does not substitute for the IAP Ig do-
main and some antibodies against the IAP Ig domain are
ineffective at costimulation. This suggests that, despite the
likely independence of IAP T cell costimulation from inte-
grins, the IAP Ig domain may interact with another mole-
cule in addition to the antibody presented on the activating
surface or cell. The requirement for the IAP Ig domain ex-
ists even when the only cell in the assay is the responding
T cell, suggesting that the IAP Ig domain recognizes an-
other plasma membrane molecule on the same cell, as it
does in forming a signaling complex with b3 integrins. Be-
cause of the requirement for proximity to the TCR com-
plex, some component of that complex is a good candidate
for interaction with the IAP Ig domain. Alternatively, if
IAP acts as a membrane channel, it is possible that the Ig
domain interacts directly with the multiply membrane-
spanning domain to regulate channel activity.
The exact role of IAP in the immune response remains
to be determined. While we have found that anti-IAP can
costimulate T cell responses, it is not known under what
circumstances IAP ligation is necessary or aids T cell activa-
tion. Since anti-IAP stimulates activation with antigen
presentation by CH27, we assume that these APCs do not
express endogenous IAP ligand. The discovery that throm-
bospondin is an IAP ligand (7) suggests that its interaction
with IAP might play a role in T cell activation at sites of in-
flammation, where thrombospondin is transiently a com-
ponent of the extracellular matrix. This would provide a
mechanism by which IAP, which is constituitively ex-
pressed, would only be engaged at inflammatory sites, lead-
ing to optimal T cell activation as required for an effective
immune response.
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